LBA1_PR Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

Saved in:
Bibliographic Details
Published in:Journal of thoracic oncology 2016-04, Vol.11 (4), p.S152-S152
Main Authors: Ramalingam, S., Yang, J.C.-H., Lee, C.K., Kurata, T., Kim, D.-W., John, T., Nogami, N., Ohe, Y., Janne, P.A.
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1556-0864
1556-1380
DOI:10.1016/S1556-0864(16)30324-0